

1 **Clinical characteristics of COVID-19 in children and**
2 **adolescents: a systematic review and meta-analysis**

3 **Name of the Authors:**

4 Lixiang Lou^{1a}, Hui Zhang^{1a}, Baoming Tang², Ming Li², Zeqing Li², Haifang Cao³,
5 Jian Li⁴, Yuliang Chong⁵, Zhaowei Li^{2,*}

6 **Affiliation:**

7 Lixiang Lou¹: The Graduate School of Qinghai University, Xining, China

8 Email:loulixiang@qq.com

9 Hui Zhang^{1a}: The Graduate School of Qinghai University, Xining, China

10 Email:zhanghui10157@163.com

11 Baoming Tang²: Department of Traumatology orthopedics, Affiliated Hospital of
12 Qinghai University, Xining, China

13 Email:18697126038@163.com

14 Ming Li²: Department of pediatric, Affiliated Hospital of Qinghai University, Xining,
15 China

16 Email:865880047@qq.com

17 Zeqing Li²: Department of Traumatology orthopedics, Affiliated Hospital of Qinghai
18 University, Xining, China

19 Email:lzq611206771@163.com

20 Haifang Cao³: Department of Liver Diseases, The Fourth People's Hospital of Qinghai
21 Province (Qinghai Specialized Hospital of Infectious Diseases), Xining,
22 China

23 Email:1736853849@qq.com

24 Jian Li⁴: The First Affiliated Hospital of Bengbu Medical College, Bengbu, China

25 Email:543715871@qq.com

26 Yuliang Chong⁵: Affiliated Hospital of Yanbian University, Yanbian, China

27 Email:chongyuliang@163.com

28 ***Corresponding Author:** Zhaowei Li, Dr

29 Department of Traumatology orthopedics, Affiliated Hospital of Qinghai University,
30 Xining, China

31 **Address:**

32 29 Tongren Road, Xining, Qinghai, China

33 **Postal code:**810000

34 Zhaowei Li^{2,*} Email:Lzw6230@163.com

35 Phone : 86013709743526

36 ^a These authors contributed equally to the manuscript.

37 **Competing interests:** No authors have competing interests in this research.

38 **Funding:** This research did not receive any specific grant from funding agencies in
39 the public, commercial, or not-for-profit sectors.

40 **Contributors:** All the authors designed the study. LL, HZ, ZL and BT designed the
41 literature search and searched the articles. LL, HZ, ML, YC, JL, and BT contributed
42 to statistical analysis, interpretation of data and data review. LL, HZ wrote the first
43 draft of the article. All the authors revised the article and approved the final version.

44 **Summary**

45 **Background:** Although the number of COVID-19 (coronavirus disease 2019) cases
46 continues to increase globally, there are few studies on the clinical characteristics of
47 children and adolescents with COVID-19.

48 **Objective:** To conduct a comprehensive systematic evaluation and meta-analysis of
49 the clinical characteristics of COVID-19 in children and adolescents to better guide
50 the response to the current epidemic.

51 **Methods:** We searched PubMed, Embase, the Cochrane Library, Web of Science,
52 CNKI (Chinese database), Clinical Trials.gov and chictr.org.cn (China). The
53 methodological quality of the included literature was evaluated using the Quality
54 Assessment Tool for Case Series Studies. Meta-analysis was performed using STATA
55 14.0. Heterogeneity was assessed by the Q statistic and quantified using I^2 . We used
56 fixed-effects or random-effects models to pool clinical data in the meta-analysis.
57 Publication bias was evaluated by the Begg's test.

58 **Results:** We analyzed 49 studies involving 1627 patients. In the pooled data, the most

59 common clinical symptoms were fever (56% [0.50–0.61]) and cough (45%
60 [0.39–0.51]). The most common laboratory abnormalities were elevated procalcitonin
61 (40% [0.23–0.57]), elevated lactate dehydrogenase (31% [0.19–0.43]), increased
62 lymphocyte count (28% [0.17–0.42]), increased creatine kinase (28% [0.18– 0.40]),
63 and elevated C-reactive protein (26% [0.17–0.36]). The most common abnormalities
64 determined by computed tomography were lower-lobe involvement (56% [0.42-
65 0.70]), ground-glass opacities (33% [0.25–0.42]), bilateral pneumonia (32% [0.24-
66 0.40]), patchy shadowing (31% [0.18- 0.45]), and upper lobe involvement (30%
67 [0.20- 0.41]).

68 **Conclusion:** Disease severity among children and adolescents with COVID-19 was
69 milder than that among adult patients, with a greater proportion of mild and
70 asymptomatic cases, and thus, the diagnosis of COVID-19 and control of the infection
71 source are more challenging.

72 **Keywords:** COVID-19; 2019-nCoV; Child; Adolescent; review; meta-analysis.

73 **Introduction**

74 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly
75 discovered coronavirus responsible for the coronavirus disease 2019 (COVID-19),
76 which was first reported in Wuhan City, Hubei Province in December 2019 [1]. On
77 January 12, 2020, the World Health Organization (WHO) officially named the novel
78 coronavirus "2019 novel coronavirus (2019-nCoV)" [2]. So far, over 20 million
79 people live with COVID-19 worldwide, with 750,000 deaths, and the death toll is still
80 rising. Currently, COVID-19 outbreaks are continuing to spread across the globe.
81 SARS-CoV-2 is spread by between-human transmission via droplets or close contact
82 [3], but there are also studies showing that it can be transmitted from person to person
83 by aerosols [4]. Fecal-oral routes may also constitute a potential person-to-person
84 transmission route. Several studies have reported that the virus may still be
85 transmitted from COVID-19-positive stool samples even after COVID-19 with
86 negative detection of viral ribonucleic acid from nasopharyngeal swabs [5,13]. The

87 development of the immune system in children and adolescents is not yet perfect, and
88 it is easy for various types of viruses to cause infections. COVID-19 is a novel
89 infectious disease. The population lacks immunity and is generally susceptible in
90 crowded conditions. However, a study has found that COVID-19 in children below
91 the age of 10 years constituted only 0.35% of cases [6]. It is essential to identify and
92 control patients who are suspected of having COVID-19 as early as possible and to
93 prevent the further spread of the epidemic by controlling the source of infection and
94 cutting off transmission pathways. Although the number of COVID-19 cases
95 continues to grow globally, there are few studies focusing on the clinical
96 manifestations, laboratory tests, chest imaging examinations, and complications for
97 children and adolescents with COVID-19. We conducted a systematic review and
98 meta-analysis of the clinical characteristics of children and adolescents to describe
99 comprehensive characteristics of COVID-19 in children and adolescents to better treat
100 and control the current outbreak.

101 **1 Methods**

102 **1.1 Retrieval of published studies**

103 PRISMA and MOOSE guidelines were used to conduct this systematic
104 review and meta-analysis [7-8]. We used the Medical Subject Heading (MeSH) terms
105 and corresponding keywords to develop the search strategy. The search terms
106 included: "Child (MeSH)" or "children" or "Adolescent (MeSH)" or "Teens" and
107 "COVID-19 (MeSH)" or "SARS-CoV-2 infection" and "clinical characteristics" or
108 "clinical features". We searched PubMed, Embase, the Cochrane Library, Web of
109 Science, and CNKI (Chinese database). We also searched Clinical Trials.gov and
110 chict.org.cn (China) to find unpublished studies. There were no restrictions on use,
111 including no language restrictions. The search time limit was from the establishment
112 of each database to July 10, 2020. To ensure comprehensiveness of the search strategy,
113 the search tasks were performed independently by two researchers (LL, BT). Details

114 of the search strategy are provided as shown in Supplementary [Text S1](#).

115 **1.2 Inclusion and exclusion criteria**

116 **1.2.1 Inclusion criteria**

117 Research type: Not limited by research type or research design. Research object:
118 Participants included children and adolescents between the ages of 1 and 18 years,
119 cases with positive nucleic acid tests in patients with COVID-19. Intervention was
120 unrestricted. Outcomes included clinical manifestations, laboratory examinations,
121 and CT examinations.

122 **1.2.2 Exclusion criteria**

123 Infants less than 1 year of age. Fewer than 4 cases reported. Surveillance
124 reports, community outbreaks, review papers, commentary articles, conference papers,
125 duplicated reports, reports for which the full text cannot be obtained. There is no
126 definite measure or laboratory marker for the diagnosis of COVID-19. The
127 outcome was not clear.

128 **1.3 Data extraction**

129 Two researchers (HZ, LL) independently screened and cross-checked the
130 literature regarding the inclusion and exclusion criteria. Any disagreement was
131 resolved by discussion between the two reviewers. A customized form was used to
132 record the first author, publication time, design of the trial, country, the number of
133 COVID-19 patients, ages, sexes, durations between onset of symptoms and
134 hospitalization (days), times of patient examinations, diagnostic criteria for
135 COVID-19, clinical symptoms, laboratory outcomes, chest CT findings, and
136 supportive treatment. In addition, we screened them according to whether blood or
137 respiratory samples were positive by real-time polymerase chain reaction tests for
138 SARS-CoV-2 nucleic acid.

139 **1.4 Quality assessment of included meta-analyses**

140 For the case series study, we used the Quality Assessment Tool for Case Series
141 Studies to evaluate article suitability for systematic review [9]. Each item was
142 scored as either 0 or 1 point based on the scoring criteria, and scores were summed
143 across items to generate an overall quality score ranging from 0 to 9. Overall scores
144 were classified as low risk (≥ 7 points), moderate risk (5–6 points), or high risk (0–4
145 points). Two evaluators (HZ, LL) separately performed quality assessment. Any
146 disagreements were resolved through discussion among the investigators.

147 **1.5 Statistical analysis**

148 Meta-analysis was performed using STATA 14.0. A random-effects model was
149 used to compute the combined prevalence and 95% confidence intervals (CI). We
150 calculated the pooled incidence of clinical symptoms, laboratory findings, and chest
151 CT findings. Heterogeneity was assessed using Cochran's Q test with a significance
152 level of $p < 0.1$ and quantified using the I^2 statistic. Heterogeneity was quantified
153 using the I-squared (I^2) statistic and categorized as low ($I^2 < 25\%$), moderate (I^2
154 $= 25\text{--}50\%$) or high ($I^2 > 50\%$). A model of fixed effect (FE) was set with 95% CI if no
155 statistical evidence of heterogeneity existed ($p \geq 0.1$, $I^2 \leq 50\%$), while a model of
156 random effect (RE) was applied to estimate pooled effect with 95% confidence
157 intervals (CI) if statistical heterogeneity was found ($p < 0.1$, $I^2 > 50\%$). If significant
158 heterogeneity ($p < 0.1$, $I^2 > 75\%$) was detected, we used sensitivity analysis to explore
159 its possible sources. A random-effects model was used if the reason for heterogeneity
160 could not be identified. Publication bias was detected using Begg's test. Probability (p)
161 values less than 0.05 were considered statistically significant.

162 **2 Results**

163 **2.1 Systematic search results**

164 The search strategy initially identified 467 publications, including 60 from

165 PubMed, 131 from Embase, 5 from Cochrane, and 196 from Web of Science. Search
166 results from different sources were entered into an EndNote library, from which 146
167 duplicates and 366 irrelevant studies were removed. Among the remaining 101
168 articles selected for full-text reading, 52 studies were removed. Finally, 49 studies
169 [10-58] were included in the meta-analysis involving 1627 participants. Only three of
170 49 included studies reported critically ill patients [15,26,31]. These critically ill
171 patients were not excluded from the meta-analysis. Mechanical ventilation analysis
172 included only critically ill patients. We extracted data based on different outcome
173 indicators and then conducted a single-arm meta-analysis. Figure 1 illustrates the
174 detailed process of the literature review.

175 **2.2 Study characteristics**

176 The characteristics of the studies are displayed in Table 1. The studies included
177 were published between February 26, 2020 and June 29, 2020. Fifty articles including
178 41 (84%) English papers and 8 (16%) Chinese papers were included in our study, and
179 all were journal articles. Patients were from six countries: 41 from China, 4 from the
180 United States, 1 from Italy, 1 from France, 1 from Turkey, and 1 from Iran. All
181 included studies were retrospective studies; one was a case-control study, and the
182 remainder were retrospective case series. The number of patients enrolled in each
183 study ranged from 4 to 157, and patients' ages ranged from 1 to 18 years. Male
184 patients accounted for 53%, and female patients accounted for 47%. All patients were
185 confirmed to be positive for SARS-CoV-2 nucleic acid by respiratory or blood
186 sample.

187 **2.3 Methodological assessment of the included literature**

188 For the evidence of effectiveness meta-analysis, we used the Quality
189 Assessment Tool for Case Series Studies to evaluate article suitability for the
190 systematic review. Among the 49 studies included, 43 studies were rated as low risk
191 of bias, 6 studies as moderate, and none were rated as high risk of bias (Table 2).

192 **2.4 Meta-analysis results**

193 We meta-analyzed the prevalence of 18 clinically relevant symptoms ([Table 3](#)),
194 the prevalence of 12 laboratory outcomes ([Table 4](#)), and the prevalence of 9 chest CT
195 findings ([Table 5](#)). The analysis of the 48 articles included showed that boys (53%
196 [0.50–0.56]) had a higher prevalence of COVID-19 than did girls (47% [0.44–0.50]).

197 Among the 18 frequently reported clinical symptoms ([Table 3](#)), the incidence of
198 clinical symptoms of COVID-19 in children and adolescents was 86% [95% CI
199 0.77–0.93], and the most common clinical symptoms were fever (56% [0.50–0.61])
200 ([Supplementary Figs S 1](#)), cough (45% [0.39–0.51]) ([Supplementary Figs S 2](#)),
201 sneezing (14% [0.08–0.22]), and vomiting (14% [0.06–0.24]). Other symptoms
202 included diarrhea (12% [0.06–0.19]), anhelation (11% [0.04–0.19]), sore throat (10%
203 [0.05–0.16]), headache (10% [0.04–0.17]), fatigue (9% [0.05–0.15]), myalgia (8%
204 [0.02–0.17]), increased sputum volume (7% [0.03–0.13]), and abdominal pain (6%
205 [0.01–0.12]). In addition, the meta-analysis included 3 studies with critically ill
206 children and showed that the incidence of mechanical ventilation in severely ill
207 children was 38% [0.27–0.50]. All the above results were statistically significant
208 ($p < 0.05$). There was no statistical significance ($P > 0.05$) for the analyzed results
209 for renal insufficiency or mortality. Of the 49 included studies, only 3 case studies of
210 critically ill children reported deaths, and no deaths were reported in the remaining 47
211 studies. Publication bias was found for symptoms of sore throat, anhelation, headache,
212 diarrhea, and vomiting, and no publication bias was found for the remaining clinical
213 symptoms.

214 Among the 13 frequently reported laboratory findings ([Table 4](#)), the most
215 common abnormalities in laboratory examinations were elevated procalcitonin (40%
216 [0.23–0.57]), elevated lactate dehydrogenase (31% [0.19–0.43]), increased
217 lymphocyte count (28% [0.17–0.42]), increased creatine kinase (28% [0.18–0.40]),
218 and elevated C-reactive protein (26% [0.17–0.36]) ([Supplementary Figs S 3, 4, 5, 6](#)
219 [and 7](#)). Additional laboratory findings included elevated AST (24% [0.09–0.43]),
220 decreased leukocyte count (21% [0.13–0.29]), elevated D-dimer (19% [0.09–0.31]),

221 reduced lymphocyte count (15% [0.09–0.21]), increased leukocyte count (15%
222 [0.07–0.25]), and elevated ALT (7% [0.05–0.10]). Because only two studies reported
223 elevated creatinine, we did not perform a meta-analysis. All the results described
224 above were statistically significant ($p < 0.05$). Begg's test indicated significant
225 publication bias for decreased leukocyte count, elevated ALT, and elevated D-dimers,
226 and no remaining laboratory findings showed significant publication bias at $p < 0.05$.

227 Among the 9 frequently reported chest CT findings (Table 5), in the included 26
228 studies, the prevalence of chest CT examinations showing infection was 67%
229 [0.58–0.76] (Supplementary Figs S 8). The most common abnormalities from chest
230 CT examination were lower lobe involvement (56% [0.42-0.70]), ground-glass
231 opacities (33% [0.25–0.42]), bilateral pneumonia (32% [0.24-0.40]), patchy shadows
232 (31% [0.18-0.45]), and upper lobe involvement (30% [0.20-0.41]) (Supplementary
233 Figs S 9, 10, 11, 12 and 13). Other outcomes included unilateral pneumonia (26%
234 [0.22-0.30]), tubercles (13% [0.06-0.21]), pleural fluid (3% [0.00-0.08]). All the
235 abovementioned results were statistically significant ($p < 0.05$). Publication bias
236 was found for bilateral pneumonia, and there was no evidence of significant
237 publication bias among the remaining 9 included studies.

238 **3 Discussion**

239 This meta-analysis summarizes the latest and most comprehensive study for
240 clinical characteristics of COVID-19 in children and adolescents, from the first report
241 of COVID-19 to July 10, 2020, including clinical features, laboratory outcomes, and
242 chest CT findings. We conducted a systematic review and meta-analysis of 49 studies
243 involving 1627 patients. The proportion of boys was significantly higher than that of
244 girls, also consistent with previous studies, according to the synthesis results of our
245 meta-analysis. Compared with the two previous systematic reviews on this topic, we
246 have included more studies and analyzed 40 results in detail.

247 The main clinical features in children and adolescents with COVID-19 were
248 fever (56%), cough (45%), sneezing (14%), vomiting (14%), and other less common

249 results included diarrhea (12%), anhelation (11%), sore throat (10%), headache (10%),
250 fatigue (9%), myalgia (8%), increased sputum volume (7%), and abdominal pain (6%).
251 According to a previous study of COVID-19 in adult patients, the main clinical
252 features of COVID-19 were fever, cough, and fatigue [59-60]. In this study of
253 children and adolescents, patients with symptoms of sneezing and vomiting also
254 accounted for reasonably large percentages. Previous studies have found that nasal
255 congestion, runny nose and diarrhea were less common in children than in adults
256 [61-63]. Critical or fatal pediatric COVID-19 cases were rare, and children with
257 COVID-19 showed less severe clinical symptoms than did adults. In addition, one
258 study showed that children may be less likely to be infected, and may show milder
259 symptoms if they are infected [63]. Therefore, children and adolescents are more
260 likely to have potential hidden infections, which should attract the attention of
261 clinicians and parents of children.

262 The most common laboratory abnormalities were elevated procalcitonin
263 (40%), elevated lactate dehydrogenase (31%), increased lymphocyte count (28%),
264 elevated creatine kinase (28%) and elevated C-reactive protein (26%). These
265 laboratory abnormalities indicate clear viral infection. Previous studies have found the
266 most common laboratory test abnormalities in adult patients to be elevated C-reactive
267 protein and reduced lymphocyte count [59-60]. All these abnormal laboratory markers
268 are nonspecific, so their clinical applications are limited. According to the findings of
269 our study, the elevated procalcitonin, elevated lactate dehydrogenase and increased
270 lymphocyte count may appear as nonspecific markers in children and adolescents.
271 Previous research has suggested that mortality, acute respiratory distress syndrome
272 (ARDS), headache, increased leukocyte count, and elevated lactate dehydrogenase are
273 significantly higher in studies with a larger proportion of older patients [59]. When
274 evaluating suspicious cases, doctors cannot rely on these laboratory abnormalities to
275 rule out or confirm the diagnosis of COVID-19 [59]. One study suggested that these
276 abnormalities may be related to the cytokine storm caused by infection [64]. Recently,
277 another study revealed that COVID-19 might mainly affect T lymphocytes, especially
278 CD4+T cells, resulting in significant lymphopenia [65].The results of this study

279 showed that the prevalence of increased lymphocyte count in children (28%) was
280 higher than the prevalence of decreased lymphocyte count (15%), which may be
281 related to the percentage of lymphocytes elevated in the growth and development of
282 the child's immune system. In terms of liver enzymes, elevated AST (24%) was more
283 common than elevated ALT (7%), which indicates that liver function may be damaged
284 to varying degrees. In addition, reduced leukocyte count (21%) was more common
285 than increased leukocyte count (15%). Of the 49 studies reviewed, only two reported
286 elevated creatinine. Therefore, elevated creatinine was extremely rare among children
287 with COVID-19.

288 Chest CT examination was one of the important auxiliary examinations for
289 COVID-19 pneumonia, and it has a very satisfactory effectiveness for the
290 examination of lung lesions. Previous research has found that most patients have mild
291 symptoms and elevated body temperature, but pulmonary lesions are relatively
292 obvious. Li [66] found that chest CT had a low rate of missed diagnosis of COVID-19
293 (3.9%) and could thus be used as a rapid diagnostic method for this disease to
294 optimize patient management. However, CT is still limited in identifying specific
295 viruses and distinguishing viruses. Our meta-analysis showed that the prevalence of
296 children and adolescents with COVID-19 chest CT examinations showing infection
297 was 67%. A recent study of 62 adult patients with COVID-19 showed that 52 (83.9%)
298 had an abnormal chest CT scan, which was much higher than the frequency in
299 children and adolescents with an abnormal chest CT scan, consistent with previous
300 reports [67]. The results of our meta-analysis showed that the prevalence of
301 ground-glass opacity and patchy shadows were 33% and 31%, respectively. Lung
302 lesions of patients with COVID-19 showed imageology findings similar to those of
303 other viral pneumonia, mainly ground-glass opacities and patchy shadows. The most
304 common position for lesions detected by CT scan was in the lower lobe (56%), while
305 incidence of upper lobe lesion was 30%. Bilateral pneumonia (32%) was more
306 common than unilateral pneumonia (26%). A study of adult COVID-19 patients
307 showed that bilateral pneumonia was present in 73.2% of cases, indicating that adults
308 are more likely to experience bilateral lung infection than are children and adolescents

309 [59]. The results of this study found that tubercles (13%) and pleural fluid (3%) rarely
310 occur in children and adolescents with COVID-19. Chang et al. found that, compared
311 with SARS, COVID-19 has prominent characteristics in children, and the typical
312 appearance of chest CT is ground-glass opacity, which is also consistent with our
313 study [68]. Other CT findings, such as air bronchogram and lymphadenopathy, are
314 less common [69].

315 Among the 49 articles included, only 3 studies of critically ill children reported
316 deaths. Among the 1627 patients included, only 7 deaths occurred, and the overall
317 mortality was lower than the reported adult mortality (3.6%) [59]. Compared with
318 other common viral diseases, the number of cases of COVID-19 in children and
319 adolescents is small, and the mortality is low, which is very gratifying.

320 There are also several limitations to our systematic review and meta-analysis.
321 First, all reported cases were retrospective studies, and there was a high degree of
322 heterogeneity among the results of the study. Because there were many studies
323 included, it is difficult to avoid heterogeneity. No subgroup analysis was performed
324 on different age groups of the included children and adolescents. Second, the current
325 COVID-19 pandemic has not been effectively controlled. Our study was analyzed
326 during the COVID-19 outbreak. Most of the included patients were from China, and
327 there may be certain geographical and ethnic differences. Subgroup analysis was not
328 performed, which may also bias the results of the analysis.

329 **4 Conclusion**

330 This meta-analysis provides a comprehensive review of the clinical
331 characteristics of COVID-19 in children and adolescents. The main clinical features
332 of children and adolescents were fever and cough. The most frequently reported
333 laboratory abnormalities were elevated procalcitonin, elevated lactate dehydrogenase,
334 increased lymphocyte count, increased creatine kinase, and elevated C-reactive
335 protein. From chest computed tomography, the most common lesion site was the
336 lower lobe. Bilateral pneumonia was more common than unilateral pneumonia, and

337 the main manifestations were ground-glass opacities and patchy shadowing. The
338 condition of children and adolescents with COVID-19 was milder than that of adult
339 patients, with a greater proportion of asymptomatic and mild cases, and specific
340 diagnosis and source-of-infection control were more challenging.

341

342 **Declarations**

343 **Ethics approval and consent to participate**

344 Not applicable. This article does not contain any studies with human participants
345 performed by any of the authors.

346 **Consent for publication**

347 All participating authors provide consent for publication.

348 **Availability of data and materials**

349 All data generated or analyzed during this study are included in this article.

350 **Competing interests**

351 The authors declare that they have no competing interests.

352 **Funding**

353 The authors state that this work has not received financial support.

354 **Authors' contributions**

355 All the authors designed the study. LL, HZ, ZL and BT designed the literature search
356 and searched the articles. LL, HZ, ML, YC, JL, and BT contributed to statistical
357 analysis, interpretation of data and data review. LL and HZ wrote the first draft of the
358 article. All the authors revised the article and approved the final version.

359 **Acknowledgements**

360 Not applicable.

361 **References**

- 362 [1] Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global
363 health concern. *Lancet*. 2020;395(10223):470–473. doi:
364 10.1016/S0140-6736(20)30185-9.
365 [2] World Health Organization. Clinical management of severe acute respiratory

- 366 infection when when novelcoronavirus(nCoV) infection
367 issuspected:interimguidance,25January2020[R].WHO,2020.
- 368 [3] Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S,
369 Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA. SARS-CoV-2 cell entry
370 depends on ACE2 and TMPRSS2 and is blocked by a clinically proven
371 proteaseinhibitor. *Cell*. 2020 Mar 5.
- 372 [4] van Doremalen, Neeltje, Trenton Bushmaker, Dylan H. Morris, Myndi G.
373 Holbrook,Amandine Gamble, Brandi N. Williamson, Azaibi Tamin et al. "Aerosol and
374 surfacestability of SARS-CoV-2 as compared with SARS-CoV-1." *New England*
375 *Journal of Medicine* (2020).
- 376 [5] Xu, Yi, Xufang Li, Bing Zhu, Huiying Liang, Chunxiao Fang, Yu Gong, Qiaozhi
377 Guo et al. "Characteristics of pediatric SARS-CoV-2 infection and potential evidence
378 for
379 persistent fecal viral shedding." *Nature Medicine* (2020):
380 1-4.doi:10.1038/s41591-020-0817-4.
- 381 [6] YangY LQ, LiuM , et al. Epidemiological and clinical features of the 2019 novel
382 coronavirus outbreak in China. medRxiv preprint 2020
- 383 [7] Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting
384 systematic reviews and meta-analyses of studies that evaluate healthcare interventions:
385 explanation and elaboration. *BMJ*. 2009;339:b2700. Published 2009 Jul 21.
386 doi:10.1136/bmj.b2700
- 387 [8] Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in
388 epidemiology: a proposal for reporting. *Meta-analysis Of Observational Studies in*
389 *Epidemiology (MOOSE) group*. *JAMA*. 2000;283(15):2008-2012.
390 doi:10.1001/jama.283.15.2008
- 391 [9] American National Institute of Health. [https://www.nhlbi.nih.gov/health-topics/
392 study-quality-assessment-tools](https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools) .
- 393 [10] Mohammadi A, Mohebbi I, Khademvatani K, et al. Clinical and radiological
394 characteristics of pediatric patients with COVID-19: focus on imaging findings
395 [published online ahead of print, 2020 Jun 13]. *Jpn J Radiol*. 2020;1-6.
396 doi:10.1007/s11604-020-01003-6
- 397 [11] Tang A, Xu W, Chen P, et al. A retrospective study of the clinical characteristics
398 of COVID-19 infection in 26 children[J]. medRxiv, 2020. doi:
399 10.1101/2020.03.08.20029710
- 400 [12] Li B, Shen J, Li L, Yu C. Radiographic and Clinical Features of Children With
401 Coronavirus Disease (COVID-19) Pneumonia. *Indian Pediatr*. 2020;57(5):423-426.
402 doi:10.1007/s13312-020-1816-8
- 403 [13] Cai J, Xu J, Lin D, et al. A Case Series of children with 2019 novel coronavirus
404 infection: clinical and epidemiological features [published online ahead of print, 2020
405 Feb 28]. *Clin Infect Dis*. 2020;ciaa198. doi:10.1093/cid/ciaa198
- 406 [14] Foster CE, Moulton EA, Munoz FM, et al. Coronavirus Disease 2019 in Children
407 Cared for at Texas Children's Hospital: Initial Clinical Characteristics and
408 Outcomes. *J Pediatric Infect Dis Soc*. 2020;9(3):373-377. doi:10.1093/jpids/piaa072
- 409 [15] Sun D, Li H, Lu XX, et al. Clinical features of severe pediatric patients with

- 410 coronavirus disease 2019 in Wuhan: a single center's observational study. *World J*
411 *Pediatr.* 2020;16(3):251-259. doi:10.1007/s12519-020-00354-4
- 412 [16] Feng K, Yun Y X, Wang X F, et al. Analysis of CT features of 15 children with
413 2019 novel coronavirus infection. *Zhonghua er ke za zhi= Chinese journal of*
414 *pediatrics*, 2020, 58: E007-E007. doi: 10.3760/cma.j.cn112140-20200210-00071
- 415 [17] Ma H, Hu J, Tian J, et al. A single-center, retrospective study of COVID-19
416 features in children: a descriptive investigation. *BMC Med.* 2020;18(1):123.
417 Published 2020 May 6. doi:10.1186/s12916-020-01596-9
- 418 [18] Mannheim J, Gretsch S, Layden JE, Fricchione MJ. Characteristics of
419 Hospitalized Pediatric COVID-19 Cases - Chicago, Illinois, March - April 2020
420 [published online ahead of print, 2020 Jun 1]. *J Pediatric Infect Dis Soc.* 2020;pii:070.
421 doi:10.1093/jpids/piaa070
- 422 [19] Lan L, Xu D, Xia C, Wang S, Yu M, Xu H. Early CT Findings of Coronavirus
423 Disease 2019 (COVID-19) in Asymptomatic Children: A Single-Center Experience.
424 *Korean J Radiol.* 2020;21(7):919-924. doi:10.3348/kjr.2020.0231
- 425 [20] Zhu L, Wang J, Huang R, et al. Clinical characteristics of a case series of
426 children with coronavirus disease 2019. *Pediatr Pulmonol.* 2020;55(6):1430-1432.
427 doi:10.1002/ppul.24767
- 428 [21] Liu YJ, Chen P, Liu ZS, et al. Clinical features of asymptomatic or subclinical
429 COVID-19 in children. *Chinese Journal of Contemporary Pediatrics*, 2020, 22(6): 578.
430 doi:10.7499/j.issn.1008-8830.2004088(in chinese)
- 431 [22] Ma H, Shao J, Wang Y, et al. High resolution CT features of COVID-19 in
432 children. *Chinese Journal of Radiology (China)*, 2020, 54(4) : 310-313. doi:
433 10.3760/cma.j.cn112149-20200206-00100
- 434 [23] Ma YL, Xia SY, Wang M, et al. Clinical features of children with SARS-CoV-2
435 infection: an analysis of 115 cases. *Chinese Journal of Contemporary Pediatrics*, 2020,
436 22(4): 290-293. doi:10.7499/j.issn.1008-8830.2003016(in chinese)
- 437 [24] Liu M, Song Z, Xiao K. High-Resolution Computed Tomography Manifestations
438 of 5 Pediatric Patients With 2019 Novel Coronavirus. *J Comput Assist Tomogr.*
439 2020;44(3):311-313. doi:10.1097/RCT.0000000000001023
- 440 [25] Korkmaz MF, Türe E, Dorum BA, Kılıç ZB. The Epidemiological and Clinical
441 Characteristics of 81 Children with COVID-19 in a Pandemic Hospital in Turkey: an
442 Observational Cohort Study. *J Korean Med Sci.* 2020;35(25):e236. Published 2020
443 Jun 29. doi:10.3346/jkms.2020.35.e236
- 444 [26] Oualha M, Bendavid M, Berteloot L, et al. Severe and fatal forms of COVID-19
445 in children. *Arch Pediatr.* 2020;27(5):235-238. doi:10.1016/j.arcped.2020.05.010
- 446 [27] Parri N, Magistà AM, Marchetti F, et al. Characteristic of COVID-19 infection in
447 pediatric patients: early findings from two Italian Pediatric Research Networks. *Eur J*
448 *Pediatr.* 2020;179(8):1315-1323. doi:10.1007/s00431-020-03683-8
- 449 [28] Peng H, Gao P, Xu Q, et al. Coronavirus disease 2019 in children: Characteristics,
450 antimicrobial treatment, and outcomes. *J Clin Virol.* 2020;128:104425.
451 doi:10.1016/j.jcv.2020.104425
- 452 [29] Qiu H, Wu J, Hong L, Luo Y, Song Q, Chen D. Clinical and epidemiological
453 features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China:

- 454 an observational cohort study. *Lancet Infect Dis.* 2020;20(6):689-696.
455 doi:10.1016/S1473-3099(20)30198-5
- 456 [30] Steinberger S, Lin B, Bernheim A, et al. CT Features of Coronavirus Disease
457 (COVID-19) in 30 Pediatric Patients [published online ahead of print, 2020 May
458 22]. *AJR Am J Roentgenol.* 2020;1-9. doi:10.2214/AJR.20.23145
- 459 [31] Shekerdemian LS, Mahmood NR, Wolfe KK, et al. Characteristics and Outcomes
460 of Children With Coronavirus Disease 2019 (COVID-19) Infection Admitted to US
461 and Canadian Pediatric Intensive Care Units [published online ahead of print, 2020
462 May 11]. *JAMA Pediatr.* 2020;10.1001/jamapediatrics.2020.1948.
463 doi:10.1001/jamapediatrics.2020.1948
- 464 [32] Shen Q, Guo W, Guo T, et al. Novel coronavirus infection in children outside of
465 Wuhan, China. *Pediatr Pulmonol.* 2020;55(6):1424-1429. doi:10.1002/ppul.24762
- 466 [33] Su L, Ma X, Yu H, et al. The different clinical characteristics of corona virus
467 disease cases between children and their families in China - the character of children
468 with COVID-19. *Emerg Microbes Infect.* 2020;9(1):707-713.
469 doi:10.1080/22221751.2020.1744483
- 470 [34] Tan X, Huang J, Zhao F, et al. Clinical features of children with SARS-CoV-2
471 infection: an analysis of 13 cases from Changsha, China. *Zhongguo dang dai er ke za
472 zhi= Chinese journal of contemporary pediatrics,* 2020, 22(4): 294.
473 doi:10.7499/j.issn.1008-8830.2003199
- 474 [35] Tan YP, Tan BY, Pan J, Wu J, Zeng SZ, Wei HY. Epidemiologic and clinical
475 characteristics of 10 children with coronavirus disease 2019 in Changsha, China. *J
476 Clin Virol.* 2020;127:104353. doi:10.1016/j.jcv.2020.104353
- 477 [36] Waltuch T, Gill P, Zinns LE, et al. Features of COVID-19 post-infectious
478 cytokine release syndrome in children presenting to the emergency department
479 [published online ahead of print, 2020 May 23]. *Am J Emerg Med.*
480 2020;S0735-6757(20)30403-4. doi:10.1016/j.ajem.2020.05.058
- 481 [37] Du W, Yu J, Wang H, et al. Clinical characteristics of COVID-19 in children
482 compared with adults in Shandong Province, China. *Infection.* 2020;48(3):445-452.
483 doi:10.1007/s15010-020-01427-2
- 484 [38] Song W, Li J, Zou N, Guan W, Pan J, Xu W. Clinical features of pediatric
485 patients with coronavirus disease (COVID-19). *J Clin Virol.* 2020;127:104377.
486 doi:10.1016/j.jcv.2020.104377
- 487 [39] Wu H, Zhu H, Yuan C, et al. Clinical and Immune Features of Hospitalized
488 Pediatric Patients With Coronavirus Disease 2019 (COVID-19) in Wuhan, China.
489 *JAMA Netw Open.* 2020;3(6):e2010895. Published 2020 Jun 1.
490 doi:10.1001/jamanetworkopen.2020.10895
- 491 [40] Wu Q, Xing Y, Shi L, et al. Coinfection and Other Clinical Characteristics of
492 COVID-19 in Children. *Pediatrics.* 2020;146(1):e20200961.
493 doi:10.1542/peds.2020-0961
- 494 [41] Xia W, Shao J, Guo Y, Peng X, Li Z, Hu D. Clinical and CT features in pediatric
495 patients with COVID-19 infection: Different points from adults. *Pediatr Pulmonol.*
496 2020;55(5):1169-1174. doi:10.1002/ppul.24718
- 497 [42] Xu H, Liu E, Xie J, et al. A follow-up study of children infected with

- 498 SARS-CoV-2 from western China. *Ann Transl Med.* 2020;8(10):623.
499 doi:10.21037/atm-20-3192
- 500 [43] Xu H, Liu E, Xie J, et al. A follow-up study of children infected with
501 SARS-CoV-2 from western China. *Ann Transl Med.* 2020;8(10):623.
502 doi:10.21037/atm-20-3192
- 503 [44] Lu Y, Wen H, Rong D, Zhou Z, Liu H. Clinical characteristics and radiological
504 features of children infected with the 2019 novel coronavirus. *Clin Radiol.*
505 2020;75(7):520-525. doi:10.1016/j.crad.2020.04.010
- 506 [45] Han YN, Feng ZW, Sun LN, et al. A comparative-descriptive analysis of clinical
507 characteristics in 2019-coronavirus-infected children and adults [published online
508 ahead of print, 2020 Apr 6]. *J Med Virol.* 2020;10.1002/jmv.25835.
509 doi:10.1002/jmv.25835
- 510 [46] Li Y, Cao J, Zhang X, Liu G, Wu X, Wu B. Chest CT imaging characteristics of
511 COVID-19 pneumonia in preschool children: a retrospective study. *BMC Pediatr.*
512 2020;20(1):227. Published 2020 May 18. doi:10.1186/s12887-020-02140-7
- 513 [47] Zheng F, Liao C, Fan QH, et al. Clinical Characteristics of Children with
514 Coronavirus Disease 2019 in Hubei, China. *Curr Med Sci.* 2020;40(2):275-280.
515 doi:10.1007/s11596-020-2172-6
- 516 [48] Zheng G, Wang B, Zhang H, et al. Clinical characteristics of acute respiratory
517 syndrome with SARS-CoV-2 infection in children in South China [published online
518 ahead of print, 2020 Jun 24]. *Pediatr Pulmonol.* 2020;10.1002/ppul.24921.
519 doi:10.1002/ppul.24921
- 520 [49] Zhong Z, Xie X, Huang W, et al. Chest CT findings and clinical features of
521 coronavirus disease 2019 in children. *Journal of Central South University(Medical
522 sciences).* 2020;45(3):236-242. doi:10.11817/j.issn.1672-7347.2020.200206 (in
523 chinese)
- 524 [50] Zhu L, Wang J, Huang R, et al. Clinical characteristics of a case series of
525 children with coronavirus disease 2019. *Pediatr Pulmonol.* 2020;55(6):1430-1432.
526 doi:10.1002/ppul.24767
- 527 [51] Huang XP, Xie SH, Jiang LL, et al. Analysis of clinical characteristics and
528 imaging characteristics of COVID-19 in children in Gannan region. *Journal of
529 Gannan Medical University.*2020,40(03):239-242.
530 doi:10.3969/j.issn.1001-5779.2020.03.005(in chinese)
- 531 [52] Wu HP, Li BF, Chen X, et al. Clinical features of coronavirus disease 2019 in
532 children aged <18 years in Jiangxi,China: an analysis of 23 cases. *Chinese Journal of
533 Contemporary Pediatrics.*2020,22(05):419-424. doi:
534 10.7499/j.issn.1008-8830.2003202(in chinese)
- 535 [53] Li Q, Peng X, Sun Z, et al. Clinical and imaging characteristics of children with
536 corona virus disease 2019 (COVID-19). *Radiol Practice,* 2020, 35: 277-80.
537 doi:10.13609/j.cnki.1000-0313.2020.03.007
- 538 [54] Liu J, Luo W, Deng Z, et al. Clinical and epidemiological characteristics of 91
539 children conformed with COVID-19. *Chin J Nosocomiol,* 2020, 30: 1645-9.
540 doi:10.11816/cn.ni.2020-200550
- 541 [55] Wang KJ, Xu L, Yin Hui, et al. Clinical and CT Imaging Findings of Novel

- 542 Coronavirus Pneumonia in Children. Journal of Hubei University of
543 Medicine.2020,39(02):134-138. doi:10.13819/j.issn.2096-708X.2020.02.007(in
544 chinese)
- 545 [56] Yang L, Li Z, Xu H, et al. Epidemiological and clinical characteristics of 10
546 children with coronavirus disease (COVID-19) in Jinan City. Journal of Shandong
547 University(Health Sciences).2020,58(04):36-39.
548 doi:10.6040/j.issn.1671-7554.0.2020.305(in chinese)
- 549 [57] Yin H, Wu HY, Chen J, et al. Clinical characteristics and bedside lung ultrasound
550 findings of family-clustered pediatric COVID-19. Guangxi Medical
551 Journal.2020,42(10):1281-1284. doi:10.11675/j.issn.0253-4304.2020.10.22(in
552 chinese)
- 553 [58] Zhang XG, Ma Y, Xiao JA, et al. Clinical characteristics of novel coronavirus
554 pneumonia in children in Jinan. Journal of Shandong University(Health
555 Sciences).2020,58(03):62-64. doi:10.6040/j.issn.1671-7554.0.2020.180(in chinese)
- 556 [59] Fu L, Wang B, Yuan T, et al. Clinical characteristics of coronavirus disease 2019
557 (COVID-19) in China: A systematic review and meta-analysis. J Infect.
558 2020;80(6):656-665. doi:10.1016/j.jinf.2020.03.041
- 559 [60] Li LQ, Huang T, Wang YQ, et al. COVID-19 patients' clinical characteristics,
560 discharge rate, and fatality rate of meta-analysis. J Med Virol. 2020;92(6):577-583.
561 doi:10.1002/jmv.25757
- 562 [61] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019
563 novel coronavirus in Wuhan, China. Lancet. 2020. 395(10223): 497-506.
- 564 [62] Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of
565 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive
566 study.Lancet. 2020. 395(10223): 507-513.
- 567 [63] Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of
568 Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020 .
- 569 [64] Chen L, Liu H G, Liu W, et al. Analysis of clinical features of 29 patients with
570 2019 novel coronavirus pneumonia[J]. Zhonghua jie he he hu xi za zhi= Zhonghua
571 jiehe he huxi zazhi= Chinese journal of tuberculosis and respiratory diseases, 2020,
572 43: E005-E005.
- 573 [65] Chen G., Wu D., Guo W., et al. Clinical and immunologic features in severe and
574 moderate forms of coronavirus disease 2019.2020:medRxiv2020.02.16.20023903.
- 575 [66] Li Y, Xia L. Coronavirus Disease 2019 (COVID-19): Role of Chest CT in
576 Diagnosis and Management. AJR Am J Roentgenol. 2020;214(6):1280-1286.
577 doi:10.2214/AJR.20.22954
- 578 [67] Zhou S, Wang Y, Zhu T, Xia L. CT Features of Coronavirus Disease 2019
579 (COVID-19) Pneumonia in 62 Patients in Wuhan, China. AJR Am J Roentgenol.
580 2020;214(6):1287-1294. doi:10.2214/AJR.20.22975
- 581 [68] Chang TH, Wu JL, Chang LY. Clinical characteristics and diagnostic challenges
582 of pediatric COVID-19: A systematic review and meta-analysis. J Formos Med Assoc.
583 2020;119(5):982-989. doi:10.1016/j.jfma.2020.04.007
- 584 [69] Liu H, Liu F, Li J, Zhang T, Wang D, Lan W. Clinical and CT imaging features of
585 the COVID-19 pneumonia: Focus on pregnant women and children. J Infect.
586 2020;80(5):e7-e13. doi:10.1016/j.jinf.2020.03.007

587

588 **Tables**

589 **Table 1 Characteristics of studies included in the meta-analysis.**

| Authors | Types of studies (RCS/C CS) | Country | No. of cases | Sex (% male) | Age (years), median (IQR) OR mean ± SD OR range | Duration between onset of symptoms and hospitalization (median; mean ± SD [range], days) | Check patient time | Primary outcome | | |
|----------------------------------|-----------------------------|---------|--------------|--------------|---|--|--------------------|-------------------|---------------------|-------------------|
| | | | | | | | | Clinical Symptoms | Laboratory outcomes | Chest CT findings |
| Afshin et al. ^[10] | RCS | Iran | 27 | 37.0% | 4.7±4.16Y | NA | DH | A | NA | A |
| Tang et al. ^[11] | RCS | China | 26 | 34.6% | 6.9±0.7Y | 13.6±1.03 | DH | A | A | A |
| Li B et al. ^[12] | RCS | China | 22 | 54.5% | 8±6Y | NA | DH | A | NA | A |
| Cai et al. ^[13] | RCS | China | 10 | 40.0% | mean6.1Y;3-131M | NA | DH | A | A | NA |
| Catherine et al. ^[14] | RCS | America | 57 | 56.1% | median10.7Y;0.1-20.2Y | NA | DH | A | NA | NA |
| Sun et al. ^[15] | RCS | China | 8 | 75.0% | 2 M-15Y | NA | DH | A | A | A |
| Feng et al. ^[16] | RCS | China | 15 | 33.3% | 4-14Y | NA | DH | A | A | A |
| Ma et al. ^[17] | RCS | China | 76 | 55.3% | NA | NA | DH | A | A | A |
| Jonathan et al. ^[18] | RCS | America | 64 | 43.8% | 0-17Y | mean 4 | DH | A | NA | NA |
| Lai et al. ^[19] | RCS | China | 4 | 50.0% | 9.8±3.2Y;7-13y | 7-15 | DH | A | A | A |
| Li et al. ^[20] | RCS | China | 10 | 50.0% | 9.2±4.6Y | NA | DH | A | A | A |
| Liu Y et al. ^[21] | RCS | China | 53 | 64.2% | 8±4Y | 10±4 | DH | NA | A | NA |
| Ma H et al. ^[22] | RCS | China | 22 | 54.5% | median 4Y;2 M-14Y | 7-17 | DH | A | A | A |
| Ma YL et al. ^[23] | RCS | China | 115 | 63.5% | 51d-15Y | NA | DH | A | A | A |

| Authors | Types of studies (RCS/C CS) | Country | No. of cases | Sex (% male) | Age (years), median (IQR) OR mean ± SD OR range | Duration between onset of symptoms and hospitalization (median; mean ± SD [range], days) | Check patient time | Primary outcome | | |
|---------------------------------------|-----------------------------|---------|--------------|--------------|---|--|--------------------|-------------------|---------------------|-------------------|
| | | | | | | | | Clinical Symptoms | Laboratory outcomes | Chest CT findings |
| Liu M Q et al. ^[24] | RCS | China | 4 | 100.0% | 7.4±4.6Y | NA | DH | A | NA | NA |
| Muhammet et al. ^[25] | RCS | Turkey | 81 | 59.3% | mean 9.5Y;3.2-15.1Y | median 5;4-10 | DH | A | A | A |
| Oualha et al. ^[26] | RCS | France | 27 | 37.0% | 1 M-18Y | median 6; 2-35 | DH | A | A | A |
| Parri Niccolò et al. ^[27] | RCS | Italy | 130 | 56.2% | 0–17Y | NA | DH | A | A | A |
| Hui et al. ^[28] | RCS | China | 75 | 58.7% | 6.1±4.8Y | NA | DH | A | A | A |
| Qiu et al. ^[29] | RCS | China | 36 | 63.9% | 8.3±3.5Y | mean 14 | DH | A | A | A |
| Sharon et al. ^[30] | RCS | China | 30 | 50.0% | median10Y; 6-15Y | NA | DH | A | A | A |
| ShekerdemianLS et al. ^[31] | RCS | America | 45 | 52.1% | mean13Y;4.2-16.6Y | median 7;4-13 | DH | A | NA | NA |
| Shen et al. ^[32] | RCS | China | 9 | 33.3% | 7.6 ±3.8Y | NA | DH | A | A | A |
| Su et al. ^[33] | RCS | China | 9 | 33.3% | 4.1 ±2.9Y | NA | DH | A | A | A |
| Tan X et al. ^[34] | RCS | China | 13 | 30.8% | 7.8±5.2Y | NA | DH | A | A | A |
| Tan Y P et al. ^[35] | RCS | China | 10 | 30.0% | 7(1-12)Y | NA | DH | A | A | A |
| Temima et al. ^[36] | RCS | America | 4 | 75.0% | 10±3.6Y | NA | DH | A | A | 27 |
| Du et al. ^[37] | CCS | China | 14 | 42.9% | mean6.2Y; 0-16Y | NA | DH | A | A | A |
| Song et al. ^[38] | RCS | China | 16 | 62.5% | median8.5y;11.5 M-14Y | NA | DH | A | A | A |

| Authors | Types of studies (RCS/C CS) | Country | No. of cases | Sex (% male) | Age (years), median (IQR) OR mean ± SD OR range | Duration between onset of symptoms and hospitalization (median; mean ± SD [range], days) | Check patient time | Primary outcome | | |
|--------------------------------|-----------------------------|---------|--------------|--------------|---|--|--------------------|-------------------|---------------------|-------------------|
| | | | | | | | | Clinical Symptoms | Laboratory outcomes | Chest CT findings |
| Wu H et al. ^[39] | RCS | China | 157 | 43.9% | median7Y;1.5-10.6Y | NA | DH | A | A | A |
| Wu Q et al. ^[40] | RCS | China | 74 | 59.5% | mean6.0Y; 0.1–15.1Y | NA | DH | A | NA | A |
| Xia et al. ^[41] | RCS | China | 20 | 65.0% | 1 M-6Y | mean 2.9;8-20 | DH | A | A | A |
| Xu HG et al. ^[42] | RCS | China | 32 | 53.1% | 8.7±4.7Y | NA | DH | A | NA | A |
| Xu Y et al. ^[43] | RCS | China | 9 | NA | 7.2±5.5Y | NA | DH | A | A | A |
| Lu et al. ^[44] | RCS | China | 9 | 55.6% | 7.8±5.3Y | NA | DH | A | A | A |
| Han et al. ^[45] | RCS | China | 7 | 57.1% | mean1.3Y; 0.2-13Y | NA | DH | A | A | A |
| Li Y et al. ^[46] | RCS | China | 8 | 37.5% | 2.6±1.4Y | NA | DH | A | A | A |
| Zheng F et al. ^[47] | RCS | China | 25 | 56.0% | median3Y (2–9Y) | NA | DH | A | NA | A |
| Zheng G et al. ^[48] | RCS | China | 52 | 53.8% | median9Y (4-12Y) | mean14.5;10-17 | DH | A | NA | NA |
| Zhong Z et al. ^[49] | RCS | China | 8 | NA | 7.3±3.9Y | NA | DH | A | A | A |
| Zhu L et al. ^[50] | RCS | China | 10 | 50.0% | 9.2±4.6Y | NA | DH | A | A | A |
| Huang et al. ^[51] | RCS | China | 5 | 60.0% | 10±6.6Y | NA | DH | A | A | A |
| Wu et al. ^[52] | RCS | China | 23 | 39.1% | 3 M-17Y | 7-24 | DH | A | A | A |
| Li Q et al. ^[53] | RCS | China | 30 | 60.0% | Median6Y | NA | DH | A | NA | A |

| Authors | Types of studies (RCS/CS) | Country | No. of cases | Sex (% male) | Age (years), median (IQR) OR mean ± SD OR range | Duration between onset of symptoms and hospitalization (median; mean ± SD [range], days) | Check patient time | Primary outcome | | |
|------------------------------|---------------------------|---------|--------------|--------------|---|--|--------------------|-------------------|---------------------|-------------------|
| | | | | | | | | Clinical Symptoms | Laboratory outcomes | Chest CT findings |
| Liu J et al. ^[54] | RCS | China | 91 | 61.5% | median 4Y | NA | DH | A | A | A |
| Wang et al. ^[55] | RCS | China | 20 | 30.0% | median 2Y and 9M | NA | DH | A | A | A |
| Liu Y et al. ^[56] | RCS | China | 10 | 30.0% | 5.1±4.1Y | median 15 | DH | A | NA | NA |
| Yin et al. ^[57] | RCS | China | 15 | 26.7% | median 2Y and 8M | NA | DH | A | A | NA |
| Zang et al. ^[58] | RCS | China | 10 | 30.0% | median 4 Y; mean 4.9Y | NA | DH | A | A | A |

IQR: interquartile; RCS = Retrospective case series; CCS = Case-control study; D= day; M= month; Y= years; DH= During hospitalization; A= Available; NA = Not available.

591

592

593 **Table 2 Quality Assessment Tool for Case Series Studies.**

| Author | NIH Quality Assessment Tool for Case Series Studies | | | | | | | | | Quality (Total Quality Score) |
|----------------------------------|---|----|----|----|----|----|----|----|----|-------------------------------|
| | Q1 | Q2 | Q3 | Q4 | Q5 | Q6 | Q7 | Q8 | Q9 | |
| Afshin et al. ^[10] | 1 | 1 | 1 | NA | 1 | 1 | 1 | 1 | 1 | Good (8) |
| Tang et al. ^[11] | 1 | 1 | 1 | NA | 1 | 0 | 1 | 1 | 1 | Good (7) |
| Li B et al. ^[12] | 1 | 1 | 1 | NA | 1 | 1 | 1 | 1 | 1 | Good (8) |
| Cai et al. ^[13] | 1 | 1 | 1 | NA | 1 | 0 | 1 | 1 | 1 | Good (7) |
| Catherine et al. ^[14] | 1 | 0 | 1 | NA | 1 | 1 | 1 | 1 | 1 | Good (7) |
| Sun et al. ^[15] | 1 | 1 | 1 | NA | 1 | 1 | 1 | 1 | 1 | Good (8) |

| Author | NIH Quality Assessment Tool for Case Series Studies | | | | | | | | | Quality (Total Quality Score) |
|--------------------------------------|---|----|----|----|----|----|----|----|----|-------------------------------|
| | Q1 | Q2 | Q3 | Q4 | Q5 | Q6 | Q7 | Q8 | Q9 | |
| Feng et al. ^[16] | 1 | 0 | 1 | NA | NR | 0 | 1 | 1 | 1 | Fair (5) |
| Ma et al. ^[17] | 1 | 0 | 1 | NA | NR | 0 | 1 | 1 | 1 | Fair (5) |
| Jonathan et al. ^[18] | 1 | 1 | 1 | NA | NR | 1 | 1 | 1 | 1 | Good (7) |
| Lan et al. ^[19] | 1 | 1 | 1 | NA | 1 | 1 | 1 | 1 | 1 | Good (8) |
| Li et al. ^[20] | 1 | 1 | 1 | NA | 1 | 1 | 1 | 1 | 1 | Good (8) |
| Liu Y et al. ^[21] | 1 | 1 | 1 | NA | 1 | 1 | 1 | 1 | 1 | Good (8) |
| Ma H et al. ^[22] | 1 | 1 | 1 | NA | 0 | 1 | 1 | 1 | 1 | Good (7) |
| Ma Y L et al. ^[23] | 1 | 1 | 0 | NA | NR | 0 | 1 | 1 | 1 | Fair (5) |
| Liu M Q et al. ^[24] | 1 | 1 | NR | NA | NR | 1 | 1 | 1 | 1 | Fair (6) |
| Muhammet et al. ^[25] | 1 | 1 | 1 | NA | 1 | 1 | 1 | 1 | 1 | Good (8) |
| Oualha et al. ^[26] | 1 | 1 | 1 | NA | 1 | 0 | 1 | 1 | 1 | Good (7) |
| Parri Niccolò et al. ^[27] | 1 | 1 | 1 | NA | 1 | 0 | 1 | 1 | 1 | Good (7) |
| Hui et al. ^[28] | 1 | 1 | 1 | NA | 1 | 1 | 1 | 1 | 1 | Good (8) |
| Qiu et al. ^[29] | 1 | 1 | 1 | NA | NR | 1 | 1 | 1 | 1 | Good (7) |
| Sharon et al. ^[30] | 1 | 1 | 1 | NA | NR | 1 | 1 | 1 | 1 | Good (7) |
| ShekerdemanLS et al. ^[31] | 1 | 1 | 1 | NA | 1 | 1 | 1 | 1 | 1 | Good (8) |
| Shen et al. ^[32] | 1 | 1 | 1 | NA | 1 | 1 | 1 | 1 | 1 | Good (8) |

| Author | NIH Quality Assessment Tool for Case Series Studies | | | | | | | | | Quality (Total Quality Score) |
|--------------------------------|---|----|----|----|----|----|----|----|----|-------------------------------|
| | Q1 | Q2 | Q3 | Q4 | Q5 | Q6 | Q7 | Q8 | Q9 | |
| Su et al. ^[33] | 1 | 1 | 1 | NA | NR | 1 | 1 | 1 | 1 | Good (7) |
| Tan X et al. ^[34] | 1 | 1 | 1 | NA | 1 | 1 | 1 | 1 | 1 | Good (8) |
| Tan Y P et al. ^[35] | 1 | 1 | 1 | NA | 1 | 1 | 1 | 1 | 1 | Good (8) |
| Temima et al. ^[36] | 1 | 1 | 1 | NA | 1 | 1 | 1 | 1 | 1 | Good (8) |
| Du et al. ^[37] | 1 | 1 | 1 | 1 | NR | 1 | 1 | 1 | 1 | Good (8) |
| Song et al. ^[38] | 1 | 1 | 1 | NA | 1 | 1 | 1 | 1 | 1 | Good (8) |
| Wu H et al. ^[39] | 1 | 1 | 1 | NA | NR | 0 | 1 | 1 | 1 | Fair (6) |
| Wu Q et al. ^[40] | 1 | 1 | 1 | NA | 1 | 1 | 1 | 1 | 1 | Good (8) |
| Xia et al. ^[41] | 1 | 0 | 1 | NA | 0 | 1 | 1 | 1 | 1 | Fair (6) |
| Xu HG et al. ^[42] | 1 | 1 | 1 | NA | 1 | 1 | 1 | 1 | 1 | Good (8) |
| Xu Y et al. ^[43] | 1 | 1 | 1 | NA | NR | 1 | 1 | 1 | 1 | Good (7) |
| Lu et al. ^[44] | 1 | 1 | 1 | NA | NR | 1 | 1 | 1 | 1 | Good (7) |
| Han et al. ^[45] | 1 | 1 | 1 | NA | 1 | 1 | 1 | 1 | 1 | Good (8) |
| Li Y et al. ^[46] | 1 | 1 | 1 | NA | 1 | 1 | 1 | 1 | 1 | Good (8) |
| Zheng F et al. ^[47] | 1 | 0 | 1 | NA | 1 | 1 | 1 | 1 | 1 | Good (7) |
| Zheng G et al. ^[48] | 1 | 0 | 1 | NA | 1 | 1 | 1 | 1 | 1 | Good (7) |
| Zhong Z et al. ^[49] | 1 | 1 | 1 | NA | NR | 1 | 1 | 1 | 1 | Good (7) |
| Zhu L et al. ^[50] | 1 | 1 | 1 | NA | 1 | 1 | 1 | 1 | 1 | Good (8) |

| Author | NIH Quality Assessment Tool for Case Series Studies | | | | | | | | | Quality (Total Quality Score) |
|------------------------------|---|----|----|----|----|----|----|----|----|-------------------------------|
| | Q1 | Q2 | Q3 | Q4 | Q5 | Q6 | Q7 | Q8 | Q9 | |
| Huang et al. ^[51] | 1 | 1 | 1 | NA | NR | 1 | 1 | 1 | 1 | Good (7) |
| Wu et al. ^[52] | 1 | 1 | 1 | NA | 1 | 0 | 1 | 1 | 1 | Good (7) |
| Li Q et al. ^[53] | 1 | 0 | 1 | NA | 1 | 1 | 1 | 1 | 1 | Good (7) |
| Liu J et al. ^[54] | 1 | 1 | 1 | NA | 1 | 1 | 1 | 1 | 1 | Good (8) |
| Wang et al. ^[55] | 1 | 0 | 1 | NA | 1 | 1 | 1 | 1 | 1 | Good (7) |
| Liu Y et al. ^[56] | 1 | 1 | 1 | NA | 1 | 1 | 1 | 1 | 1 | Good (8) |
| Yin et al. ^[57] | 1 | 1 | 1 | NA | 1 | 1 | 1 | 1 | 1 | Good (8) |
| Zang et al. ^[58] | 1 | 1 | 1 | NA | 1 | 1 | 1 | 1 | 1 | Good (8) |

594 Good: Met 7–9 criteria, Fair: Met 4–6 criteria, Poor: Met 0–3 criteria. NA = not applicable, NIH = National Institutes of Health, NR = not reported, Q1: Was study
 595 question or objective clearly stated?, Q2: Was study population clearly and fully described, including case definition?, Q3: Were cases consecutive?, Q4: Were
 596 subjects comparable?, Q5: Was intervention clearly described?, Q6: Were outcome measures clearly defined, valid, reliable, and implemented consistently across
 597 all study participants?, Q7: Was length of follow-up adequate?, Q8: Were statistical methods well-described?, Q9: Were results well-described?
 598

599 **Table 3 Clinical Symptoms**

| Outcomes | No. includ-ed studies | No. events/total | I ² | Q test P= | Fixed pooled | Random pooled | 95% Conf. Interval | Test of Z= | Test of P= | Begg's Test P= |
|------------------------|-----------------------|------------------|----------------|-----------|--------------|---------------|--------------------|------------|------------|----------------|
| With clinical symptoms | 35 | 796/984 | 90.67% | 0.00 | NA | 0.86 | 0.77–0.93 | 18.71 | 0.00 | 0.158 |
| Fever | 44 | 729/1404 | 72.68% | 0.00 | NA | 0.56 | 0.50–0.61 | 25.06 | 0.00 | 0.418 |
| Cough | 43 | 664/1393 | 71.36% | 0.00 | NA | 0.45 | 0.39–0.51 | 21.90 | 0.00 | 0.509 |

| Outcomes | No. included studies | No. events/total | I ² | Q test P= | Fixed pooled | Random pooled | 95% Conf. Interval | Test of Z= | Test of P= | Begg's Test P= |
|-------------------------|----------------------|------------------|----------------|-----------|--------------|---------------|--------------------|------------|------------|----------------|
| Sneezing | 13 | 111/627 | 80.58% | 0.00 | NA | 0.14 | 0.08–0.22 | 6.13 | 0.00 | 0.669 |
| Sore throat | 19 | 85/759 | 76.67% | 0.00 | NA | 0.10 | 0.05–0.16 | 5.84 | 0.00 | 0.039 |
| Increased sputum volume | 5 | 12/146 | 0.00% | 0.58 | 0.07 | NA | 0.03–0.13 | 4.81 | 0.00 | 0.806 |
| Anhelation | 14 | 70/607 | 84.96% | 0.00 | NA | 0.11 | 0.04–0.19 | 4.55 | 0.00 | 0.037 |
| Myalgia | 8 | 38/347 | 76.06% | 0.00 | NA | 0.08 | 0.02–0.17 | 3.36 | 0.00 | 0.386 |
| Fatigue | 15 | 99/755 | 75.04% | 0.00 | NA | 0.09 | 0.05–0.15 | 5.75 | 0.00 | 0.586 |
| Headache | 14 | 71/654 | 80.61% | 0.00 | NA | 0.10 | 0.04–0.17 | 4.79 | 0.00 | 0.042 |
| Abdominal Pain | 7 | 17/244 | 53.45% | 0.04 | NA | 0.06 | 0.01–0.12 | 3.08 | 0.00 | 0.133 |
| Diarrhea | 24 | 142/1100 | 87.06% | 0.00 | NA | 0.12 | 0.06–0.19 | 5.91 | 0.00 | 0.001 |
| Vomiting | 18 | 120/693 | 88.08% | 0.00 | NA | 0.14 | 0.06–0.24 | 4.86 | 0.00 | 0.010 |
| Renal insufficiency | 3 | 6/178 | 71.29% | 0.03 | NA | 0.03 | 0.00–0.11 | 1.89 | 0.06 | 0.296 |
| Mechanical ventilation | 3 | 30/78 | 0.00% | 0.96 | 0.38 | NA | 0.27–0.50 | 9.62 | 0.00 | 0.296 |
| Death | 49 | 7/1627 | 0.00% | 0.98 | 0.00 | NA | 0.00–0.00 | 0.00 | 1.00 | 0.000 |
| Percentage of boys | 47 | 852/1613 | 31.37% | 0.02 | 0.53 | NA | 0.50–0.56 | 41.17 | 0.00 | 0.229 |
| Proportion of girls | 47 | 761/1613 | 31.37% | 0.02 | 0.47 | NA | 0.44–0.50 | 38.86 | 0.00 | 0.229 |

600

601

Table 4 Laboratory outcomes

| Outcomes | No. included studies | No. events/total | I ² | Q test P= | Fixed pooled | Random pooled | 95% Conf. Interval | Test of Z= | Test of P= | Begg's Test P= |
|--------------|----------------------|------------------|----------------|-----------|--------------|---------------|--------------------|------------|------------|----------------|
| Leukocytes ↑ | 14 | 37/335 | 70.45% | 0.00 | NA | 0.15 | 0.07–0.25 | 4.92 | 0.00 | 0.024 |

| Outcomes | No.includ- ed studies | No. events/total | I ² | Q test P= | Fixed pooled | Random pooled | 95% Conf. Interval | Test of Z= | Test of P= | Begg's Test P= |
|----------------------------|--------------------------|---------------------|----------------|--------------|-----------------|------------------|-----------------------|---------------|---------------|-------------------|
| Leukocytes ↓ | 24 | 135/645 | 78.23% | 0.00 | NA | 0.21 | 0.13–0.29 | 8.02 | 0.00 | 0.196 |
| lymphocyte ↑ | 19 | 126/454 | 84.64% | 0.00 | NA | 0.28 | 0.17–0.42 | 6.67 | 0.00 | 0.276 |
| lymphocyte ↓ | 19 | 88/554 | 66.42% | 0.00 | NA | 0.15 | 0.09–0.21 | 7.47 | 0.00 | 0.674 |
| ALT ↑ | 13 | 45/448 | 39.76% | 0.07 | 0.07 | NA | 0.05–0.10 | 6.11 | 0.00 | 0.032 |
| AST ↑ | 7 | 47/242 | 78.83% | 0.00 | NA | 0.24 | 0.09–0.43 | 4.27 | 0.00 | 0.095 |
| Creatinine ↑ | 2 | 4/121 | NA | NA | NA | NA | NA | NA | NA | NA |
| Creatine Kinase ↑ | 13 | 108/444 | 77.70% | 0.00 | NA | 0.28 | 0.18–0.40 | 7.88 | 0.00 | 0.271 |
| Lactate dehydrogenase ↑ | 13 | 121/468 | 80.93% | 0.00 | NA | 0.31 | 0.19–0.43 | 7.47 | 0.00 | 0.299 |
| C reactive protein ↑ | 21 | 196/710 | 84.45% | 0.00 | NA | 0.26 | 0.17–0.36 | 8.33 | 0.00 | 0.880 |
| D - dimer ↑ | 9 | 35/234 | 68.53% | 0.00 | NA | 0.19 | 0.09–0.31 | 5.06 | 0.00 | 0.022 |
| Procalcitonin ↑ | 13 | 195/495 | 91.14% | 0.00 | NA | 0.40 | 0.23–0.57 | 6.58 | 0.00 | 0.951 |

602 ALT: Alanine aminotransferase; AST: Aspartate aminotransferase.

603 **Table 5 Chest CT findings**


| Outcomes | No. includ- ed studies | No. events/total | I ² | Q test P= | Fixed pooled | Random pooled | 95% Conf. Interval | Test of Z= | Test of P= | Begg's Test P= |
|---------------------|---------------------------------|---------------------|----------------|--------------|-----------------|------------------|-----------------------|---------------|---------------|-------------------|
| CT showed infection | 25 | 386/574 | 78.19% | 0.00 | NA | 0.67 | 0.58–0.76 | 17.32 | 0.00 | 0.453 |
| Bilateral pneumonia | 20 | 191/694 | 74.19% | 0.00 | NA | 0.32 | 0.24–0.40 | 11.80 | 0.00 | 0.019 |

| Outcomes | No. included studies | No. events/total | I ² | Q test P= | Fixed pooled | Random pooled | 95% Conf. Interval | Test of Z= | Test of P= | Begg's Test P= |
|---------------------------|----------------------|------------------|----------------|-----------|--------------|---------------|--------------------|------------|------------|----------------|
| Unilateral pneumonia | 16 | 151/552 | 32.92% | 0.10 | 0.26 | NA | 0.22–0.30 | 14.62 | 0.00 | 0.892 |
| Involvement in upper lobe | 9 | 81/237 | 60.59% | 0.01 | NA | 0.30 | 0.20–0.41 | 8.79 | 0.00 | 0.208 |
| Involvement in lower lobe | 10 | 150/262 | 77.52% | 0.00 | NA | 0.56 | 0.42–0.70 | 10.56 | 0.00 | 0.857 |
| Patchy shadowing | 5 | 69/195 | 67.69% | 0.01 | NA | 0.31 | 0.18–0.45 | 6.92 | 0.00 | 0.221 |
| Ground-glass opacities | 27 | 311/970 | 84.44% | 0.00 | NA | 0.33 | 0.25–0.42 | 11.50 | 0.00 | 0.217 |
| Pleural fluid | 3 | 6/218 | 56.13% | 0.10 | NA | 0.03 | 0.00–0.08 | 2.18 | 0.03 | 0.296 |
| Tubercles | 4 | 13/93 | 33.52% | 0.21 | 0.13 | NA | 0.06–0.21 | 4.64 | 0.00 | 0.089 |

604 CT: Computed Tomography.


605 **Figures**

606 **Figure 1** Flow chart of literature search and selection of studies.




607
608
609
610
611
612
613
614
615
616

617 **Figure S 1** Forest plots of the prevalence of fever among children and adolescents
 618 with COVID-19.




619
 620
 621
 622
 623
 624
 625
 626
 627
 628

629 **Figure S 2** Forest plots of the prevalence of cough among children and adolescents
 630 with COVID-19.




631
 632
 633
 634
 635
 636
 637
 638
 639
 640

641 **Figure S 3** Forest plots of the prevalence of elevated procalcitonin among children
 642 and adolescents with COVID-19.




643
 644
 645
 646
 647
 648
 649
 650
 651
 652
 653
 654
 655
 656
 657
 658

659 **Figure S 4** Forest plots of the prevalence of elevated lactate dehydrogenase among
 660 children and adolescents with COVID-19.




661
 662
 663
 664
 665
 666
 667
 668
 669
 670
 671
 672
 673
 674
 675
 676

677 **Figure S 5** Forest plots of the prevalence of increased lymphocyte count among
 678 children and adolescents with COVID-19.




679
 680
 681
 682
 683
 684
 685
 686
 687
 688
 689
 690
 691
 692
 693

694 **Figure S 6** Forest plots of the prevalence of increased creatine kinase among children
 695 and adolescents with COVID-19.



696
 697
 698
 699
 700
 701
 702
 703
 704
 705
 706
 707
 708
 709
 710
 711

712 **Figure S 7** Forest plots of the prevalence of C-reactive protein among children and
 713 adolescents with COVID-19.



714

715

716

717

718

719

720


721

722

723

724

725 **Figure S 8** Forest plots of the prevalence of chest CT examinations showing infection
 726 among children and adolescents with COVID-19.



727

728

729

730

731

732


733

734

735


736

737 **Figure S 9** Forest plots of the prevalence of lower lobe involvement among children
 738 and adolescents with COVID-19.




739
 740
 741
 742
 743
 744
 745
 746
 747
 748
 749
 750
 751

752 **Figure S 10** Forest plots of the prevalence of ground-glass opacities among children
 753 and adolescents with COVID-19.



754
 755
 756
 757
 758
 759
 760
 761
 762
 763

764 **Figure S 11** Forest plots of the prevalence of bilateral pneumonia among children and
 765 adolescents with COVID-19.



766

767

768

769

770

771

772


773

774

775

776

777 **Figure S 12** Forest plots of the prevalence of patchy shadows among children and
778 adolescents with COVID-19.



779

780

781

782

783

784

785

786

787

788


789

790

791

792

793 **Figure S 13** Forest plots of the prevalence of upper lobe involvement among children
 794 and adolescents with COVID-19.



795
 796
 797